Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840, a late-stage therapy for Wilson disease, and a radiopharmaceutical pipeline targeting advanced cancers, including MNPR-101-Zr and MNPR-101-Lu in Phase 1 clinical trials and MNPR-101-Ac225 in late preclinical development.
| Website | https://www.monopartx.com/ |
| Employees | 22 (18 on RocketReach) |
| Founded | 2015 |
| Address | 1000 Skokie Blvd, Wilmette, Illinois 60091, US |
| Technologies |
JavaScript
,
HTML
,
Google Analytics
+10 more
(view full list)
|
| Industry | Biotechnology Research, Drug Discovery, Biotechnology |
| Keywords | Clinical Stage Biopharmaceutical, Biopharmaceutical Research, Pharmaceutical Research, Cancer Therapeutics, Drug Development Pipeline, Biotechnology, Oncology Drug Development, Novel Cancer Therapies, Cancer Treatment Research, Targeted Cancer Therapy, Improving Quality Of Life, New Cancer Treatments |
| Competitors | Sorrento Therapeutics, Inc., Xencor, Zymeworks Inc., Akebia Therapeutics, Immunovant, Celsion Corporation, Galectin Therapeutics, Oncorus, Apexigen, Marinomed Biotech AG +32 more (view full list) |
Looking for a particular Monopar Therapeutics Inc. employee's phone or email?
Chandler Robinson is the CEO of Monopar Therapeutics Inc..
18 people are employed at Monopar Therapeutics Inc..
Monopar Therapeutics Inc. is based in Wilmette, Illinois.